May 6, 2021
John Mulcahy PhD, President and CEO, SiteOne Therapeutics talks about broadening their pipeline from acute pain to hypersensitivity disorders like chronic cough and itching. Approach is to inhibit voltage-gated subtype sodium channel Nav1.7, a genetically validated target for pain. Stopping the pain signal in the peripheral nervous system before it gets to the spinal cord avoids some of the liabilities with existing pain medication like opioids. Lead candidate is now an intravenous analgesic showing proof of concept for the treatment of acute pain and itch.
#pain #hypersensitivity #sodiumchannels #opioids